13 Small Cap Stocks Analysts Are Bullish On

Page 10 of 12

3. Janux Therapeutics, Inc. (NASDAQ:JANX)

Market Cap: $1.40 billion

Analyst Upside: 238.98%

Number of Hedge Fund Holders: 41

Janux Therapeutics, Inc. (NASDAQ:JANX) is one of the 13 Small Cap Stocks Analysts Are Bullish On. On May 14, JonesTrading analyst Soumit Roy maintained a bullish stance on Janux Therapeutics, Inc. (NASDAQ:JANX), giving it a Buy rating with a $90 price target. The analyst based the rating on the company’s promising developments and future potential.

Janux Therapeutics, Inc. (NASDAQ:JANX) is expected to release additional data from its Phase 1 trials for JANX007 and JANX008 in H2 2025, which the analyst projects could affect its market position.

JANX007, a T cell-engaging antibody, is expected to be in competition with Pluvicto. Despite a complicated administration, Pluvicto already holds a considerable market share. However, the analyst reasoned that JANX007 could experience faster market adoption if it exhibits efficacy comparable to Pluvicto, which would positively impact Janux Therapeutics, Inc. (NASDAQ:JANX).

The analyst also noted that the safety profile of JANX007 would be critical, especially in regard to steroid use post-CRS resolution. Therefore, Roy reasoned that investor interest could grow with a favorable safety outcome.

Janux Therapeutics, Inc. (NASDAQ:JANX) is a preclinical stage biopharmaceutical company that develops therapeutics based on the Tumor Activated T Cell Engager platform technology. The company develops tumor-activated immunotherapies for cancer through two bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr).

Page 10 of 12